Cd was given to control and MT-TG mice orally (0.3-300 //mol/kg, 200 fiCUkg) or intravenously (0.03-10 /xmol/kg, 20 ^Ci/kg). Cd concentrations in 15 tissues were quantified 7 days later. Higher MT concentrations in tissues of MT-TG mice had no appreciable effects on the concentration of Cd in tissues compared to controls. An exception to this was the MT-TG mice given the highest dose of Cd (300 //mol Cd/kg, po), which had twice the tissue Cd concentration of controls. Approximately 60% of the Cd administered iv was retained in the tissues; retention of Cd in MT-TG mice was similar to that in controls. In both control and MT-TG mice only 0.1-0.3% of Cd administered po was retained, except for 1-3% at the higher doses (100 and 300 fimollkg). Cd administered iv distributed mainly to the liver (70%) and kidney (10%) and was independent of dose. In contrast, when administered po, distribution of Cd to the liver increased from 40 to 75% of the dose, whereas distribution to kidney decreased from 30 to 7% as doses were increased from 0.3 to 300 /zmol/kg. No difference in pattern of Cd distribution to various organs was observed between control and MT-TG mice. These data indicate that higher concentrations of MT in MT-TG mice do not appear to inhibit the gastrointestinal absorption of Cd nor alter the organ distribution of Cd. c 1996 Society of Toxicology Cadmium (Cd) is an environmental pollutant that is toxic to a number of tissues, including kidney, liver. lung, bone, and the reproductive organs (Goering et al., 1995) . Exposure to Cd is ubiquitous. Food is the primary source of Cd for most humans. The estimated daily Cd intake ranges from 10-25 fj,g in the United States to 200-320 //g in some 1 To whom correspondence should be addressed.
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polluted areas of Japan (Elinder, 1986) . Additional sources of Cd include cigarette smoking and occupational exposure.
Cd is poorly absorbed after oral ingestion (Miller et ai, 1968; Lehman and Klaassen, 1986) . The estimated absorption of Cd is less than 5% from the gastrointestinal tract in humans and about 1% in animals (Foulkes, 1986) . Once absorbed, the movement of Cd from blood to tissue is rapid. Over 60% of the body burden of Cd is localized in liver and kidney (Decker et ai, 1957; Kotsonis and Klaassen, 1977; Lehman and Klaassen, 1986) . However, the factors that influence absorption and tissue distribution of Cd are not well understood.
Many factors have been shown to influence the absorption of Cd from the gastrointestinal tract. For example, age influences Cd absorption as more Cd is absorbed in newborn than adult animals (Sasser and Jarboe, 1977) . Gender and strain of animal influence the absorption and tissue accumulation of Cd (Kello et ai, 1979; Taguchi and Suzuki, 1981; Shaikh et ai, 1993) . Absorption of Cd is also influenced by metal ions (such as zinc, calcium, iron, and chromium), dietary constituents (Foulkes, 1986; Groten et al., 1991) , and chelating agents (Klaassen et ai, 1984; Anderson, 1989) . Dose also affects the absorption of Cd, as a greater percentage of Cd is absorbed at higher dosages (Lehman and Klaassen, 1986; Andersen, 1989) .
The distribution of Cd to tissues after oral administration is dependent on the dose of Cd administered (Lehman and Klaassen, 1986; Scheuhammer, 1988; Andersen, 1989) . At low oral doses, the highest concentration of Cd is found in kidneys. However, at high oral doses, a greater percentage of Cd distributes to liver (Lehman and Klaassen. 1986; Andersen, 1989) .
A major factor that is thought to affect Cd tissue distribution is metallothionein (MT). MT is a low-molecular-weight, metal-binding protein. One-third of the amino acid residues of MT are cysteines. These cysteine residues bind and store metal ions, with one MT molecule capable of binding 7 atoms of Cd (Kagi. 1993) . More than 60% of Cd in liver, kidney, and intestinal mucosa cytosol is bound to and detoxified by MT (Webb. 1986 ). Thus, it has been proposed that MT plays an important role in the accumulation of Cd in the body (Shaikh and Lucis, 1972; Squibb et al., 1976) and is responsible for the long biological half-life of Cd (Engstrom and Nordberg, 1979) .
MT has been proposed to trap Cd in the intestine (Foulkes and McMullen, 1986) . It was recently shown that pretreatment of rats with Zn (100 mg/kg), which increased intestinal MT 25-fold, inhibited the absorption of orally administered Cd (Sugawa and Sugawa, 1987; Min et al., 1991) . Zn pretreatment also decreased Cd distribution to liver and increased its distribution to kidneys (Min et al., 1991 (Min et al., , 1992 . Thus, MT has also been proposed to play an important role in decreasing the absorption of Cd and altering its tissue distribution.
However, the hypothesis that MT plays a major role in Cd absorption and tissue distribution is not generally agreed upon because of the following observations: (1) The concentrations of Zn used to increase MT in these studies are not physiologically relevant (Vallee and Maret, 1993) . (2) Induction of intestinal MT by Zn is not specific, as exogenous Zn produces many effects in addition to increasing MT (Iszard et al., 1995b) . In fact, Zn competes with Cd for intestinal absorption (Foulkes, 1986) . (3) Increases in MT produced by oral Cd administration do not alter Cd absorption, as determined by the intestinal perfusion model (Kello et al., 1979) . (4) Similarly, in studies where in situ intestinal loops were used, Zn-induced MT does not decrease Cd absorption (Goon and Klaassen, 1989; Ohta and Cherian, 1991) . (5) Newborn rats have much higher hepatic MT concentrations than do adult rats, and yet do not have an appreciably higher distribution of Cd to their livers (Wong and Klaassen, 1980) . Thus, the role of MT in oral Cd absorption and distribution needs to be clarified.
A transgenic mouse strain that carries 56 copies of the MT-I transgene (Palmiter et al., 1993) and has constitutively higher concentrations of MT in their tissues (Iszard et al., 1995a) was recently created. The purpose of this study was to use these transgenic mice to determine the role of higher tissue MT concentrations in Cd absorption and tissue distribution over a wide range of Cd doses.
MATERIALS AND METHODS

Chemicals. Cadmium chloride was obtained from Fisher Scientific Co. (Fair Lawn, NJ).
IO9 CdCl 2 (5.12 mCi/mg) was obtained from New England Nuclear (Boston, MA). All other chemicals were reagent grade.
Animals. Male transgenic mice (C57BL/6J x SJL background) overexpressing MT (Palmiter et al., 1993) were bred to female C57BL/6J mice. The mice were housed in AAALAC-accredited facilities at 70 ± 2°F with a 12/12-hr light/dark cycle. Mice were allowed free access to feed (Purina Laboratory Mouse Chow, St. Louis, MO) and tap water. The tails of adult mice were cut for DNA analysis to determine which mice carried the MT-I transgene as described previously (Iszard et al., 1995a) . The mice carrying the MT-I transgene were referred to as MT-TG mice, and their littermates were used as controls. Both male and female mice ages 7 to 8 months were used in the present study. Cd/kg) in a volume of 10 ml/kg. After Cd administration, a period of 7 days was allowed for the elimination of unbound Cd from the gastrointestinal tract.
Mice were anesthetized and major organs (liver, kidney, pancreas, spleen, stomach, small intestine, large intestine, heart, lung, bone, muscle, brain, and the reproductive organs) were removed and weighed.
l09 Cd content in tissues was quantified with a Packard Model 5130 auto-gamma scintillation spectrometer. Small and large intestine were analyzed with the contents included. For calculation of the amount of Cd in blood, skin, muscle, and bone, a total mass of 6.7. 20, 40, and 10%, respectively, of the body weight was assumed (Kreppel et al., 1994) .
Metallothionein assay. Liver, kidney, and small intestine (without contents) were homogenized in 10 min Tris-HCl (pH 7.4). The homogenates were centrifuged at 20,000g for 20 min, and MT concentration in the cytosols was determined by the Cd/hemoglobin radioassay (Eaton and Toal, 1982) .
Statistics. Means and standard errors were calculated. Differences between control and MT-TG mice were analyzed by the Student t test. The acceptable level of significance was set at p =s 0.05.
RESULTS
MT-TG mice have higher concentrations of MT in their tissues than control mice (Fig. 1) . In MT-TG mice, the MT concentrations in small intestine (32 vs 8.9 fig/g ), large intestine (29 vs 4.6 //g/g), stomach (108 vs 11 /xg/g), liver (115 vs 7.5 ng/g), and kidney (28 vs 5.4 //g/g) were 4-, 6-, 10-, 15-, and 5-fold over those of controls, respectively.
The retention of Cd in both groups of mice 1 week after iv administration was proportional to the dose administered (Fig. 2, top) . No difference in the whole-body retention of Cd was observed between control and MT-TG mice 1 week after intravenous Cd (0.3-10 y^mol/kg) administration. The percentage of Cd recovered was approximately 60% of the dose administered (Fig. 2, bottom) , regardless of the dose administered. The kidney/liver Cd concentration ratios after oral administration of various dosages of Cd are shown in Fig. 5 . At low doses, the concentration of Cd in kidney was approximately three times more than in liver. However, at the higher doses of Cd, more Cd distributed to liver, reducing the kidney/liver Cd concentration ratios from 3 to 0.5. There was no appreciable difference in the kidney/liver Cd concentration ratios between control and MT-TG mice.
Concentrations of Cd and MT in liver, kidney, and intestine 1 week after iv administration of Cd are shown in Fig.  6 . The concentration of Cd in tissues increased proportionally with the dose of Cd administered. There were no differences in tissue concentrations of Cd between control and MT-TG mice, except for a slightly higher Cd retention in kidneys of MT-TG mice at the two lower doses of Cd (Fig.  6, left) . MT concentrations in liver and kidney were similar in mice given the three lower dosages of Cd, but MT induction was evident at the two higher dosages of Cd. The tissue concentrations of MT were higher in the MT-TG than control mice 1 week after administration of all doses of Cd (Fig. 6,  right) . Figure 7 illustrates the concentration of Cd and MT in tissues 1 week after oral administration of various dosages of Cd to control and MT-TG mice. The concentration of Cd In contrast to that observed after iv administration of Cd, oral administration of Cd resulted in a dose-dependent increase in Cd retention (Fig. 3) . This is best observed in the bottom panel of Fig. 3 , where the data is plotted as percentage of the dose administered. At low doses of Cd (0.3-30 /^mol/kg), approximately 0.1 -0.3% of Cd administered po was retained in the body 1 week after administration. However, the percentage retention increased to 0.7% with 100 fj,mo\ Cd/kg po dose and further increased to 1.5-3% after the highest dose (300 ^,mol/kg). No difference in the wholebody retention of Cd was observed between control and MT-TG mice, except for the highest dose. At that dose, more Cd (3.0 vs 1.7% of the dose) was retained, and the total tissue Cd content was almost double in the MT-TG mice compared to control mice.
The relative distribution of Cd to liver and kidney is shown in Fig. 4 . Intravenously administered Cd was distributed primarily to liver (about 70% of the body burden) and kidney (about 10% of the body burden), which was independent of dose (Fig. 4, top) . In contrast, when administered increasing po dosages, the distribution of Cd to liver increased from 40 to 75% of the dose, whereas distribution to kidney decreased from 30 to 7% (Fig. 4, bottom) . No difference in the distribution of Cd to liver and kidney was observed between control and MT-TG mice following iv or po administration. 7, left). There was no appreciable difference in tissue Cd concentrations after oral administration of Cd between control and MT-TG mice, except for an approximately twofold in tissues increased with increasing oral dose of Cd. However, the increases were not proportional to dosage. A disproportional increase in Cd was found in the liver and kidney after the higher doses of Cd (100 and 300 //mol/kg) ( higher concentration of Cd in the tissues at the highest dose of Cd (300 fimol/kg). Tissue concentrations of MT (Fig. 7 , right) were similar in mice given the three lower oral dosages of Cd. Hepatic MT concentrations were increased only with the higher po doses of Cd (100 and 300 //mol/kg). Renal concentrations of MT in MT-TG mice was doubled after 10 /xmol Cd/kg, po. In contrast to MT-TG mice, the increases in renal MT in control mice were not evident until the higher po doses were given. Intestinal MT concentrations of MT-TG mice reached 68 fig MT/g tissue after oral administration of 10 ^fmol Cd/kg, but decreased to 37 fig MT/g tissue at the highest oral dose (300 fimol/kg). This result may be due to Cd toxicity. In contrast to MT-TG mice, intestinal concentrations of MT in control mice were increased less, reaching 20 fig MT/g tissue 1 week after administration of the three higher oral Cd doses. The MT concentrations in tissues of MT-TG mice were higher than in control mice 1 week after administration of all doses of Cd.
DISCUSSION
In the present study, a wide range of Cd dosages was administered to mice orally or intravenously. The lowest dose was close to the human daily exposure of Cd (Elinder, 1986) , whereas the highest dose was close to the maximum tolerated dose (Kotsonis and Klaassen, 1977; Andersen, 1989) . The retention of Cd given intravenously was shown to be independent of dosage. About 60% of Cd is retained in mice 1 week after iv administration. In contrast, the retention of Cd administered orally is much lower than that after iv administration and is dependent on the dose administered. For example, at the lower doses (0.3 to 30 //mol/kg), approximately 0.1 to 0.3% of Cd given orally was retained in the mice 1 week after administration. Therefore, the data suggest that at the lower doses of Cd, only approximately 0.2 to 0.5% of Cd is absorbed. The retention of Cd increased to 1 to 3% with high doses of Cd (100 and 300 fi,mo\ Cd/kg), corresponding to approximately 2-5% absorption of administered Cd. However, these high doses are at least 10,000 times greater than typical human exposure to Cd, based on the estimate that a 50-to 70-kg human consumes approximately 25-50 fig Cd/day (Elinder, 1986) .
The reason that a greater fraction of Cd is absorbed at high doses than low doses is not known. One possibility is that at the high doses of Cd, the endogenous intestinal MT pool is saturated with Cd (Foulkes and McMullen, 1986) , and thus Cd is not trapped in the intestinal cells, but enters the blood compartment. Results obtained with MT-TG mice in the present study argue against this possibility, as the MT-TG mice do not absorb less Cd. Another possible explanation is that these very high doses of Cd produce toxicity to the intestine. Severe mucosal impairment has been demonstrated after oral administration of high doses of CdCl 2 (300 fimo\l kg and more) (Richardson and Fox, 1974; Valburg et al., 1977; Squibb et al., 1976) . The most frequently observed histological alterations include cell swelling, widening of intercellular spaces, mitochondrial swelling, and reduction of Paneth cells (Valburg et al, \911; Phillpotts, 1986) . Thus, with increasing dosages of Cd, disruption of intercellular junctions by Cd may allow Cd to pass directly from the lumen of the intestine into the blood stream, resulting in increased tissue retention of Cd (Lehman and Klaassen, 1986; Scheuhammer, 1988; Goon and Klaassen, 1989; Andersen, 1989) . Although histopathological examination was not performed in the present study, a decrease in intestinal MT at the highest oral dose of Cd indicates enteropathy.
The importance of MT in intestinal absorption of Cd is not understood. Cd as CdCI 2 is primarily absorbed in the most proximate part of the intestine (Sorensen et al., 1993) . It has been proposed that there are two steps involved in intestinal absorption of Cd. In step 1, luminal Cd is bound to the mucosa, followed by internalization.
Step 2 involves the release of Cd for systemic distribution (Foulkes, 1986) . Many factors affect Cd absorption, which in turn influences tissue retention of Cd (Foulkes, 1986; Groten et al., 1991; Shaikh et al., 1993) . In studies where the in situ intestinal loop technique were used, increases in intestinal MT by Zn pretreatment did not appear to affect the absorption of Cd in step 1 (Foulkes and McMullen, 1986; Goon and Klaassen, 1989; Ohta and Cherian, 1991) . However, Zn-induced MT has been proposed to trap Cd in the intestine and inhibit the absorption of Cd in step 2 (Foulkes and McMullen, 1986) , resulting in decreased Cd retention in liver (Min et al., 1991 (Min et al., , 1992 . The present study using MT-TG mice argues against this hypothesis, as a decreased retention of Cd was not observed in MT-TG mice 1 week after Cd administration. In fact, more Cd was retained in liver of MT-TG mice after the highest dose of oral Cd administration. Our results support the conclusion that intestinal MT does not decrease the absorption of Cd (Lehman and Klaassen, 1986; Piotrowski et al., 1987; Scheuhammer, 1988; Goon and Klaassen, 1989) . The inhibition of Cd absorption by Zn pretreatment may be due to interaction between Zn and Cd (Foulkes, 1986; Groten et al., 1991) , rather than increased intestinal MT.
The fractional distribution of Cd to liver and kidney is dependent on the dose and route of Cd administration, and the role of MT in Cd distribution pattern is not known. Following iv administration, the majority of Cd distributes to liver (70%), with less going to kidney (10%). This distribution of Cd after iv administration is independent of dose and was similar in control and MT-TG mice. These data support our earlier conclusion that the high concentration of MT in liver of newborn animals had little or no effect on the disposition of intravenously administered Cd (Wong and Klaassen. 1980) . In contrast to iv administration, the distriat Pennsylvania State University on February 21, 2013 http://toxsci.oxfordjournals.org/ Downloaded from bution or orally administered Cd to liver increased with dose, from 40 to 75%, and distribution to kidney decreased from 30 to 7% (Fig. 4) . Andersen (1989) administered Cd po with doses from 5 to 790 ^mol/kg to mice, and reported that the fraction of the body burden in liver increased from 58 to 77%, whereas in kidney it decreased from 15 to 7.9% of the body burden. Similar dose-dependent organ distribution patterns of orally administered Cd were also observed in rats, resulting in changes in kidney/liver Cd concentration ratio (Lehman and Klaassen, 1986) . Higher tissue MT levels in MT-TG mice in the present study did not alter the organ distribution pattern of Cd, nor the changes in kidney/liver Cd concentration ratio following oral administration. These data suggest a minimal role of MT in Cd organ distribution.
The role of MT in the Cd tissue retention is not fully understood. In the present study, the retention of Cd in tissues was largely similar in control and MT-TG mice. After iv administration, the only difference observed was that slightly more Cd was found in the kidneys of MT-TG than of control mice at the lower iv doses. It is possible that there is more MT in the serum of MT-TG mice, which binds Cd and thus shifts its distribution to the kidney. CdMT is well known to have a predilection for the kidney (Valburg et ai, 1977; Maitani et ai, 1984) . However, at all other iv doses examined, higher tissue MT concentration did not result in higher Cd retention in tissues. At the highest iv dose (10 ^mol Cd/ kg), the concentrations of Cd in liver, kidney, and intestine were 20-45% higher than those of controls, but were not statistically different. The similar Cd retention profiles between control and MT-TG mice were also observed after po administration, except slightly more Cd was found in small intestine of MT-TG mice at the low po dose of 3 //mol Cd/ kg and the highest po dose of Cd (300 //mol Cd/kg). It should be noted that MT concentrations in liver (700 /xg/g tissue) and kidney (120 /xg/g tissue) of MT-TG mice were dramatically elevated following the highest dose of Cd and twice the Cd concentration in liver, kidney and intestine was found in MT-TG mice over those of controls. These data support the notion that marked increases in tissue MT concentrations may increase Cd retention (Shaikh and Lucis, 1972; Squibb et at, 1976; Engstrom and Nordberg, 1979) .
In summary, only 0.1 -0.3% of Cd given orally is retained in mice 1 week after administration. The retention of orally administered Cd is relatively constant until high doses of Cd (100 and 300 ^mol/kg) are given. The retention increases to 1 -3% of the dose with these higher doses. However, these high dosages are at least 10,000 times greater than typical human exposure to Cd. The higher concentration of MT in MT-TG mice does not appear to inhibit oral Cd absorption nor alter the organ distribution of Cd.
